

Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients

NCT06492798

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Changhai Hospital
Enrollment	76 participants

Key Eligibility Criteria

Inclusion (5)

- Meeting the diagnostic criteria for Long COVID according to WHO.
- Main symptoms assessed based on CTCAE 5.0.
- Symptoms evaluated for exclusion reasons of other diseases by relevant specialists.
- No recent plans for pregnancy (negative pregnancy test within 72 hours for women of childbearing age prior to the start of the trial), and willing to use effective non-pharmaceutical contraceptive measures during the study.
- Signed informed consent forms and agreements to participate in this clinical trial.

Exclusion (6)

- Active malignant tumors.
- Active infections.
- Abnormal liver or kidney function (ALT, AST \gt 2 times the upper limit of normal; Cr \gt 2 times the upper limit of normal).
- Women who are pregnant, lactating, or planning to become pregnant during the trial.
- Participated in other clinical trials within the last 3 months prior to screening.
- ... and 1 more (see full listing online)

Locations (1 total)

Shanghai Changhai Hospital, Shanghai, China